AZD6738 Plus Durvalumab in Biliary Tract Cancer
This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line.

Patients will be treated with AZD6738 and Durvalumab combination.
Bile Duct Cancer|Chemotherapy Effect
DRUG: AZD6738|DRUG: Durvalumab
disease control rate (DCR) of AZD6738 and Durvalumab combination, Disease control rate based on RECIST v1.1, through study completion, an average of 1 year
overall response rate (ORR) of AZD6738 and Durvalumab combination, overall response rate (ORR) based on RECIST v1.1, through study completion, an average of 1 year|progression-free survival of AZD6738 and Durvalumab combination, Time from enroll until disease progression or death, through study completion, an average of 1 year|duration of response of AZD6738 and Durvalumab combination, Time from documentation of tumor response to disease progression, through study completion, an average of 1 year|overall survival of AZD6738 and Durvalumab combination, Time from enroll until death from any cause, every 12 weeks until death or up to 5 years|Safety and tolerability as measured by number and grade of toxicity events, CTCAE v5.0, through study completion, an average of 1 year|quality of life measurement, EORTC QLQ-C30, through study completion, an average of 1 year
This is a single arm, phase II study. Advanced BTC patients who have been previously treated with immunotherapy in either the 2nd or 3rd line will be enrolled.

Patients will be treated with AZD6738 and Durvalumab combination.

One cycle consists of 4weeks. Response evaluation will be done every 8 weeks (every 2 cycles) of treatment

1. Tumor biopsy is mandatory: screening, after 8weeks (1st-response evaluation), at disease progression (PD)
2. blood sampling for biomarker study is mandatory: every cycles
3. To evaluate the metabolic changes by AZD6738 and Durvalumab combination : 18 F-FDG PET is mandatory : screening, after 8 weeks (1st-response evaluation)